Rivastigmine - Novartis
Alternative Names: ENA 713; ENA 713D; Exelon; Exelon Patch; Exelon TDS; ONO-2540; Prometax; Rivastach Patch; Rivastigmine transdermal system; SDZ 212713; SDZ ENA 713Latest Information Update: 05 Nov 2023
At a glance
- Originator Novartis
- Developer Novartis; Ono Pharmaceutical
- Class Antidementias; Phenylcarbamates; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alzheimer's disease; Dementia
- No development reported Delirium